TIGIT and gastroesophageal junction adenocarcinoma: Given the known potential of ICIs, we are exploring the addition of tiragolumab, a T-cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor, to atezolizumab and standard chemotherapy in another arm of this current clinical trial to further understand the effects of the concurrent use of ICIs with different mechanisms of action/target domains in esophageal and gastroesophageal junction adenocarcinomas, as this combination had shown positive results in lung cancer [32].